The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Biovail Corp.  (BVF) Trade Now »     Rate BVF  -  Discuss BVF  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
81.5%
Top:
0.0%
Rate BVF:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

BVF: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Bullish on BVF ... Graphic_rating_buy BVF
37%
 +33.20%
in 479 days
Hi! Thanks for reading my blog. Please keep in mind that I am only an amateur investor and please consult a professional financial advisor for any insight on personal investments.
By  ragas   (-5.04%  risk: conservative)  07/17/08 Comment


nearly 6% dividend, pharma with actual profits Graphic_rating_buy BVF
 1 %
 -47.18%
in 881 days
Consistent recover since Sep 2006.  A pharmaceutical co with actual profits trading at apprx. 17.3 p/e (TTM).  Nearly 6% dividend makes it easier to wait for further recovery.  Future takeover candidate.
By  Yomain   (-59.43%  risk: aggressive)  06/11/07 Comment






From the Blogosphere

Biovail's short selling lawsuit dismissed

Filed under: Scandals

Judge Donald S. Goldman of the Superior Court of New Jersey dismissed Biovail's (NYSE: BVF) lawsuit against SAC Capital Advisors last week, saying that he lacked jurisdiction.

The lawsuit, originally filed in 2006, accuses SAC of colluding with analysts and other firms to produce misleading research designed to drive down the company's share price -- allowing the firm to profit from its large short position in the company's stock

Goldman wrote that he had not evaluated the merit of Biovail's claims, but did say that the company had failed to show that it was entitled to d...
By  Zac Bissonnette   (-6.85%  risk: moderate)  08/24/09 Comment


Biovail Makes Good on Promise to Transform into Niche Player in CNS Diseases

With news of a second licensing deal for a Parkinson’s disease-related product in just three months, it appears that Canadian specialty company Biovail (BVF) is rapidly and surely coming good on its longer-term strategy promise of transforming itself into a niche player in CNS diseases.

<>The latest transaction struck Monday with Santhera Pharmaceuticals (SPHDF.PK) sees Biovail add fipamezole, a phase IIb drug to treat dyskinesia in Parkinson’s disease, to its expanding portfolio, for an upfront payment of $8m and up to $184m in developmental and regulatory milestones. Swiss company Santhera...
By  trackseekingalpha   (-14.31%  risk: aggressive)  08/24/09 Comment


Biovail: Dividend Cut, Recent Acquisition Positive for Shareholders

Summary:

Biovail (BVF) is in the business of selling generic drugs. Over the past 5 years, Biovail lost its way. It depended on to a number of "blockbusters" that simply did not perform to expectations. It generated growth by acquiring.
By  trackseekingalpha   (-14.31%  risk: aggressive)  06/04/09 Comment


Notable Mergers and Acquisitions of the Day 5/6: OTEX/VIGN, BVF/GSK, BORL
<>
  • Open Text Corporation (NASDAQ: OTEX) announced an agreement to acquire Vignette Corporation (NASDAQ: VIGN) for $8.00 in cash plus 0.1447 of an Open Text common share for every Vignette common share which equates to approximately US $12.70 at close of market on May 5, 2009. This represents a premium of approximately 74% above the 30 trading day average closing price of Vignette's shares and approximately 41% above the most recent closing price. This values the transaction at approximately US $310 million.
    • <>Biovail (NYSE: BVF) announced today that it has entered into an agreement to acquire...
    By  Street Insider   (+16.23%  risk: moderate)  05/06/09 Comment


    Biovail 'Still Not Getting the Attention It Deserves' - UBS

    Biovail Corp.'s (BVF) latest rights acquisition is right on strategy, but whether it proves profitable will likely remain unknown for some time to come, says UBS analyst Marc Goodman.

    On Monday, Biovail entered into an agreement with Acadia Pharmaceuticals Inc. (ACAD), to co-develop Acadia's experimental drug for Parkinson's disease psychosis ((PDP)) and Alzheimer's disease psychosis ((ADP)) in the United States and Canada. Acadia will receive an upfront $30-million cash payment from Biovail and is entitled to receive milestone payments totaling more than $300-million.
    By  trackseekingalpha   (-14.31%  risk: aggressive)  05/05/09 Comment



    ROCK-STAR INVESTORS
    Rank Name Sharpe Ratio Avg Return Followers
    1 noshoes 21.10 +35.23% 368
    2 Gerald Greene 18.14 +70.19% 206
    3 stockmarketfunding.com 17.66 +25.78% 53
    4 akiralegrand 13.47 +14.32% 60
    5 anup2104 12.13 +69.23% 34


    POPULAR STOCKS
    Symbol Company Name Sentiment
    GOOG Google Inc
    WMT WalMart Stores Inc
    MO Altria Group Inc
    GS Goldman Sachs Group Inc The
    WM Washington Mutual Inc
    PG The Procter & Gamble Company

    TODAY'S HEADLINES

    TODAY'S TOP PICKS

    		 

    StreetInsider.com on BVF

    Visit streetinsider.com


    Discussion Wall + Add  

    Be the first to start a discussion and earn 2 points.



    More Resources

    Graphic_arrow1 About Biovail Corp. - Answers.com

    Graphic_arrow1 Historical Prices - Yahoo

    Graphic_arrow1 Message Boards - BoardCentral.com

    Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




    		IN THE PRESS
    Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch